Condition

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) clinical trials and research

• 2Clinical trials
• 2Countries

All recruiting trials (2)

• APG-3288 in relapsed/refractory blood cancers

  This study tests APG-3288 alone to see if it can be safely given and what dose works best in people whose blood cancers have returned or stopped responding to standard treatments.

  Recruiting at 5 sites Phase 1 Ascentage Pharma Group Inc. · Los Angeles, California and 5 other locations · NCT07424833

• Hypofractionation Radiotherapy + Glofitamab in Relapsed/Refractory DLBCL with High Tumor Burden

  This study tests whether giving hypofractionated radiotherapy together with glofitamab helps people with relapsed/refractory DLBCL and large tumors see better responses.

  Recruiting Phase 2 Huazhong University of Science and Technology · Wuhan, Hubei · NCT06867536

Related topics

Quick answers

How many Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) clinical trials are recruiting right now?

2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (2 trials), United States (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →